Andreas Herrmann
CEO and Founder @ Baliopharm
Basel, Switzerland
Andreas Herrmann is a startup investor at Baliopharm in Basel. Dr. Andreas Herrmann is the CEO of Baliopharm AG. In 1994, he received his PhD in biochemistry in the field of neurobiology and afterwards he worked as an associate professor in the department of cardiovascular physiology at the University of Cologne. In 1996 he was cofounder of Cardion AG and since that time Dr. Herrmann has founded sevenbiotechnology companies which he also led as the CEO. In 2002 Dr. Herrmann took over Celonic GmbH and re-structured the company towards a profitable contract development and manufacturing company (CDMO) with about 70 employees at two sites. In 2011 the Celonic AG in Switzerland was sold and Baliopharm AG (Basel) was created as spin-out companies.
Last updated:
For AI agents: llms.txt
About Baliopharm
Baliopharm AG is a biotechnology company focusing on the development of novel therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer.
Baliopharm Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Andreas Herrmann
CEO and Founder
|
|||
Heimo Stroissnig
Chief Marketing Officer
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
